Characterization of circulating tumor cells starts here

...

Molecular
biology

cell
culture

cytology

isolating
rare ctc

Isolation
device

unique
advantages

Screen Cell size-isolation
device features

  • Ready to use
  • Disposable
  • Self-contained, safe handling
  • Bar coded
  • CTC separation from blood in three minutes
  • CE-IVD
learn more

The comprehensive molecular analysis of tumor cells is an essential aspect in patient management to guide precision therapy. However, tissue biopsies to obtain tumor material are often challenging and failure rates of tissue-based next generation sequencing (NGS) remain at 14% even in highly specialized precision medicine centers.

Non-invasive blood-based testing methods such as plasma cell-free DNA (cfDNA), have the potential to address this unmet need, but current assay detection rates are unsuccessful in up to 30% of advanced cancers and the failure rates in patients bearing lower-grade tumors are presumably even higher. Moreover, DNA-based analyses from plasma do not perform well in the detection of commonly occurring gene fusions due to the relatively low abundance of these DNA fragments in the blood.

To overcome these limitations, new diagnostic tools are needed to increase detection rates of the tumor-derived, actionable genetic alterations, including oncogenic fusions that are amenable to highly effective targeted therapies.

Circulating tumor cells (CTCs), being a source of tumor material, have the potential to address these questions, and can provide unique insights into in disease heterogeneity and overall disease status that may be missed by cfDNA analysis alone.
Recent improvements in CTC isolation techniques associated with improvement of molecular biology technologies make it possible to use this CTC material as a diagnostic/prognostic tool in oncology.

Screencell has developed a simple and disposable devices for CTC isolation. This technology is based on cell size, and uses specific porous membranes, allowing an optimal separation between CTCs and other blood cells. The device does not require any other equipment/machine. The blood passing through the membrane is aspirated by a disposable vacuum tube.
ScreenCell has developed 2 devices, one for cytology (cyto device), and the other for molecular biology and culture (MB device).

See more See less
...
...

Contact form

You can also fill the form below to send us a message.
We will answers you shortly



ScreenCell® Dilution Buffers

ScreenCell® Fixed Cells (FC2) Dilution Buffer The ScreenCell® FC2 dilution buffer is essentially for pathocytological studies, including cell enumeration...

learn more

ScreenCell® Live Cells (LC) Dilution Buffer

The ScreenCell® CC dilution buffer is for isolation of live cells for cell culture directly on the filter after filtration through: (i) the...

learn more

Training Courses

ScreenCell® Fixed Cells (FC2) Dilution Buffer The ScreenCell® FC2 dilution buffer is essentially for pathocytological studies, including cell enumeration...

learn more

Protocols may be customized according to project objectives

WEINBERG Robert
WEINBERG
Robert
PhD
ALCALAY Haim
ALCALAY
Haim
PhD
BENSUSSAN Armand
BENSUSSAN
Armand
PhD
DANILA Daniel
DANILA
Daniel
Oncologist
HERSHKOVITZ Dov
HERSHKOVITZ
Dov
Pathologist
MAI Sabine
MAI
Sabine
PhD
SCHROEDER Avi
SCHROEDER
Avi
Professor
THAYER Sarah
THAYER
Sarah
MD PhD
TOLEDANO Alain
TOLEDANO
Alain
Oncologist
Uzan Georges
Uzan
Georges
Chief Scientific Officer, MD
wechsler janine
wechsler
janine
Pathologist, MD
SCHLUMBERGER Nicolas
SCHLUMBERGER
Nicolas
CEO
Uzan Georges
Uzan
Georges
Chief Scientific Officer, MD
aucant cécile
aucant
cécile
Quality affairs and production manager
chemla claude
chemla
claude
General Secretary
azoulay lydie
azoulay
lydie
Executive assistant
Bouhalla Douaa
Bouhalla
Douaa
Business and Sales Executive
chemla michael
chemla
michael
Marketing, Communication and Digital
aucant cécile
aucant
cécile
Quality affairs and production manager
wechsler janine
wechsler
janine
Pathologist, MD
groult jessica
groult
jessica
R&D Engineer, PhD
ZNATY Anaëlle
ZNATY
Anaëlle
R&D Engineer
BOURGON Aline
BOURGON
Aline
Logistic and purchase
BURLION Aude
BURLION
Aude
PhD
YE fei
YE
fei
R&D Engineer, PhD
Bojin Jacques
Bojin
Jacques
Chairman of the Board
BENBUNAN Jean-Louis
BENBUNAN
Jean-Louis
Vice Chairman
ZNATY David
ZNATY
David
Board Member
VATURI Clément
VATURI
Clément
Board Member

Partnerships

Through the isolation of circulating rare cells, ScreenCell is committed to contribute to the development of non-invasive approaches to the monitoring of patients with cancer and prenatal diagnosis. We are convinced…

learn more

[ NEWS ]

[ 2021 septembre, 21 ]
5TH ACTC KALAMATA, GREECE – 22 / 25 SEPTEMBER 2021

5TH ACTC KALAMATA, GREECE – 22 / 25 SEPTEMBER 2021

learn more
[ 2021 avril, 07 ]
Non-Metastatic Esophageal Adenocarcinoma : Circulating Tumor Cells in the Course of Multimodal Tumor Treatment

Non-Metastatic Esophageal Adenocarcinoma : Circulating Tumor Cells in the Course of Multimodal Tumor Treatment

learn more
[ 2020 mai, 28 ]
Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy

Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy

learn more